3Simon, V. , D. D. Ho,and Q. Abdool Karim. HIV/AIDS epidemi- ology, pathogenesis, prevention, and treatment [ J ]. The Lancet, 2006,368 (9534) : 489-504.
4Zolopa AR, Lazzeroni LC, Rinehart A, et al. Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation : an in- ternational comparison(The GUESS Study) [ J]. Clin Infect Dis, 2005,41 ( 1 ) :92-99.
5Japour A, Mayers DI, Johnson VA, et al. Standardized peripheral blood mononuclear cell culture assay for determination of drug sus- ceptibilities of clinical human immunodeficiency virus typel iso- lates. The RV-43 Study Group, the AIDS Clinical Trials Group Vi- rology Committee Resistance Working Group [ J ]. Antimicrob A- gents Chemother, 1993,37 ( 5 ) : 1095-1101.
6Atsuko Haehiya, Saori Aizawa-Matsuoka, Marl Tanaka, et al. Rapid and Simple Phenotypie Assay for Drug Susceptibility of Hu- man lmmunodeficieney Virus Type 1 Using CCRS-Expressing He- La/CD + 4 Cell Clone 1-10 ( MAGIC5 ) [ J ]. Amimierub Agents Chemother,2001,45 ( 2 ) :495-501.
7Krowicka H, Robinson JE, Clark R, et al. Use of tissue culture cell lines to evaluate HIV antiviral resistance [ J ]. AIDS Research and Human Retmviruses, 2008,24 ( 7 ) :957 -960.
8Hertogs K, de Bethune MP, Miller V, et al. A rapid method for sim- ultaneous detection of phenotypic resistance to inhibitors of prote- ase and reverse transcriptase in recombinant human immunodefi- ciency virus type 1 isolates from patients treated with antiretroviral drugs [ J ]. Antimicrob Agents Chemother, 1998,42 ( 2 ) :269-76.
9Jan Weber,Ana C. Vazquez,Dane Winner,et al. Novel Method tor Simultaneous Quantification of Phenotypic Resistance to Matura- tion, Pmtease, Reverse Transcriptase, and Integrase HIV Inhibitors Based on 3_Gag(p2/p7/pl/p6)/PR./R.T/INT-Recombinant Viru- ses:a Useful Tool in the Muhitarget Era of Antiretroviral Therapy [ J ]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY ,2011, 5 ( 8 ) :3729-3742.
10Garcia-Lerma J,Schinazi RF, Juodawlkis AS, et al. A rapid non- culture based assay for clinical monitoring of phenotypic resist- ance of human immunodeficiency virus type 1 to lamivudine (3TC) [ J]. Antimicrobial Agents and Chemotherapy, 1999,43 (2) :264-70.
